2020
Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh riskPolypharmacy in HIV: recent insights and future directions.
Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Current Opinion In HIV And AIDS 2020, 15: 126-133. PMID: 31833963, PMCID: PMC7543953, DOI: 10.1097/coh.0000000000000608.Commentaries, Editorials and LettersConceptsSeverity of illnessInappropriate medicationsDrug interactionsActual adverse eventsSubstance useTotal drug burdenMechanism of injuryElectronic health recordsNonantiretroviral medicationsUpdate findingsMore medicationsAdverse eventsDrug burdenClinical managementPolypharmacyDirect biomarkerMedicationsModifiable mechanismsPWHSicker individualsHealth recordsStrong associationHIVInjuryIllness
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients
2008
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
Mugavero M, May M, Harris R, Saag M, Costagliola D, Egger M, Phillips A, Günthard H, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill M, Justice A, D'Arminio Monforte A, Lampe F, Miró J, Staszewski S, Sterne J. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS 2008, 22: 2481-2492. PMID: 19005271, PMCID: PMC2793403, DOI: 10.1097/qad.0b013e328318f130.Peer-Reviewed Original ResearchConceptsAntiretroviral-naïve patientsAntiretroviral therapyLopinavir/ritonavirVirologic failureClinical eventsThird drugART initiationCohort studyAntiretroviral Therapy Cohort CollaborationNaïve HIV-positive patientsHIV-positive patientsObservational cohort studyHIV Cohort StudyART regimenCohort CollaborationNaïve patientsClinical outcomesResidual confoundingClinical practicePatientsInhibitor backboneAbacavirNevirapineTherapyDrugs